Efficacy of Alirocumab, Evolocumab, and Inclisiran in Patients with Hypercholesterolemia at Increased Cardiovascular Risk

<i>Background and Objectives:</i> Lowering low-density lipoprotein (LDL-C) levels is critical for preventing atherosclerotic cardiovascular disease, yet some patients fail to reach the LDL-C targets despite available intensive lipid-lowering therapies. This study assessed the effectivene...

Full description

Bibliographic Details

Published in:	Medicina
Main Authors:	Renata Rajtar-Salwa, Beata Bobrowska, Sylwia Socha, Artur Dziewierz, Zbigniew Siudak, Jakub Batko, Stanisław Bartuś, Agata Krawczyk-Ożóg
Format:	Article
Language:	English
Published:	MDPI AG 2024-07-01
Subjects:	alirocumab evolocumab inclisiran hypercholesterolemia proprotein convertase subtilisin/kexin type 9 inhibitors
Online Access:	https://www.mdpi.com/1648-9144/60/7/1124